On November 1, 2021 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported its participation in investor conferences in November 2021 (Press release, Ideaya Biosciences, NOV 1, 2021, View Source [SID1234594055]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Northland Capital Biotech Best Ideas Event
Wednesday, November 17, 2021

CEO Roundtable with IDEAYA participation by Yujiro Hata, Chief Executive Officer, hosted by Tim Chiang, Managing Director, Senior Analyst at 9:30am ET
Panel Discussion "New Advances in Synthetic Lethality", with IDEAYA participation by Michael White Ph.D., Chief Scientific Officer, participating at 10:45am ET
Company Presentation by Yujiro Hata, Chief Executive Officer, at 1:00pm ET
Jefferies London Healthcare Conference
Thursday, November 18, 2021

Fireside chat with Yujiro Hata, Chief Executive Officer, hosted by Maury Raycroft Ph.D., Equity Research Analyst, at 6:00pm GMT
A live audio webcast of each event will be available, as permitted by conference host, at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at View Source A replay of available webcasts will be accessible for 30 days following the live event.